1. Home
  2. RVMDW vs EPM Comparison

RVMDW vs EPM Comparison

Compare RVMDW & EPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVMDW
  • EPM
  • Stock Information
  • Founded
  • RVMDW 2014
  • EPM 2003
  • Country
  • RVMDW United States
  • EPM United States
  • Employees
  • RVMDW N/A
  • EPM N/A
  • Industry
  • RVMDW
  • EPM Oil & Gas Production
  • Sector
  • RVMDW
  • EPM Energy
  • Exchange
  • RVMDW Nasdaq
  • EPM Nasdaq
  • Market Cap
  • RVMDW N/A
  • EPM N/A
  • IPO Year
  • RVMDW N/A
  • EPM 1996
  • Fundamental
  • Price
  • RVMDW $0.18
  • EPM $5.13
  • Analyst Decision
  • RVMDW
  • EPM Strong Buy
  • Analyst Count
  • RVMDW 0
  • EPM 2
  • Target Price
  • RVMDW N/A
  • EPM $7.38
  • AVG Volume (30 Days)
  • RVMDW 15.6K
  • EPM 162.0K
  • Earning Date
  • RVMDW 02-26-2025
  • EPM 02-11-2025
  • Dividend Yield
  • RVMDW N/A
  • EPM 9.36%
  • EPS Growth
  • RVMDW N/A
  • EPM N/A
  • EPS
  • RVMDW N/A
  • EPM 0.04
  • Revenue
  • RVMDW $742,000.00
  • EPM $86,423,000.00
  • Revenue This Year
  • RVMDW N/A
  • EPM $7.51
  • Revenue Next Year
  • RVMDW N/A
  • EPM N/A
  • P/E Ratio
  • RVMDW N/A
  • EPM $122.86
  • Revenue Growth
  • RVMDW N/A
  • EPM N/A
  • 52 Week Low
  • RVMDW $0.10
  • EPM $4.59
  • 52 Week High
  • RVMDW $0.12
  • EPM $6.29
  • Technical
  • Relative Strength Index (RSI)
  • RVMDW N/A
  • EPM 39.28
  • Support Level
  • RVMDW N/A
  • EPM $5.18
  • Resistance Level
  • RVMDW N/A
  • EPM $5.32
  • Average True Range (ATR)
  • RVMDW 0.00
  • EPM 0.14
  • MACD
  • RVMDW 0.00
  • EPM -0.02
  • Stochastic Oscillator
  • RVMDW 0.00
  • EPM 29.55

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: